Loading...
Johnson & Johnson
JNJ.DE•XETRA
Healthcare
Drug Manufacturers - General
€135.70
€-1.34(-0.98%)
Johnson & Johnson (JNJ.DE) Financial Performance & Statements
Review Johnson & Johnson’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
4.30%
↑ 4.30%
Operating Income Growth
-5.38%
↓ 5.38%
Net Income Growth
-59.99%
↓ 59.99%
Operating Cash Flow Growth
6.47%
↑ 6.47%
Operating Margin
24.75%
↑ 24.75%
Gross Margin
68.30%
↑ 68.30%
Net Profit Margin
24.41%
↑ 24.41%
ROE
29.95%
↑ 29.95%
ROIC
16.17%
↑ 16.17%
Johnson & Johnson (JNJ.DE) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Johnson & Johnson stock.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $38.47B | $24.11B | $19.98B | $24.88B |
| Short Term Investments | $307.00M | $417.00M | $317.00M | $597.00M |
| Cash & Short Term Investments | $38.78B | $24.52B | $20.30B | $25.48B |
| Net Receivables | $16.02B | $18.93B | $16.17B | $15.79B |
| Inventory | $12.66B | $12.44B | $12.60B | $12.17B |
| Other Current Assets | $4.09B | $0.00 | $4.17B | $4.38B |
| Total Current Assets | $71.55B | $55.89B | $53.25B | $57.82B |
| Property Plant & Equipment (Net) | $20.87B | $20.52B | $20.48B | $19.75B |
| Goodwill | $44.47B | $44.20B | $44.80B | $44.25B |
| Intangible Assets | $36.76B | $37.62B | $39.49B | $39.73B |
| Goodwill & Intangible Assets | $81.22B | $81.82B | $84.29B | $83.97B |
| Long Term Investments | $0.00 | $0.00 | $0.00 | $1.14B |
| Tax Assets | $8.49B | $10.46B | $9.35B | $9.004B |
| Other Non-Current Assets | $11.53B | $11.41B | $10.92B | $9.40B |
| Total Non-Current Assets | $122.12B | $124.21B | $125.04B | $123.27B |
| Total Assets | $193.67B | $180.10B | $178.29B | $181.09B |
| Account Payables | $9.54B | $10.31B | $8.95B | $8.85B |
| Short Term Debt | $13.90B | $5.98B | $4.46B | $9.86B |
| Tax Payables | $4.22B | $3.77B | $4.83B | $4.31B |
| Deferred Revenue | $0.00 | $0.00 | $0.00 | $4.31B |
| Other Current Liabilities | $29.24B | $30.25B | $33.51B | $30.92B |
| Total Current Liabilities | $56.90B | $50.32B | $51.76B | $53.93B |
| Long Term Debt | $38.35B | $30.65B | $31.29B | $31.64B |
| Deferred Revenue Non-Current | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred Tax Liabilities Non-Current | $2.43B | $2.45B | $2.95B | $2.63B |
| Other Non-Current Liabilities | $17.88B | $25.19B | $22.13B | $21.35B |
| Total Non-Current Liabilities | $58.66B | $58.29B | $56.37B | $55.62B |
| Capital Lease Obligations | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $115.56B | $108.61B | $108.13B | $109.55B |
| Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock | $3.12B | $3.12B | $3.12B | $3.12B |
| Retained Earnings | $162.63B | $155.79B | $155.18B | $155.36B |
| Accumulated Other Comprehensive Income/Loss | -$11.74B | -$11.74B | -$12.52B | -$11.25B |
| Total Stockholders Equity | $78.11B | $71.49B | $70.16B | $71.54B |
| Total Equity | $78.11B | $71.49B | $70.16B | $71.54B |
| Total Liabilities & Stockholders Equity | $193.67B | $180.10B | $178.29B | $181.09B |
| Total Investments | $307.00M | $417.00M | $317.00M | $597.00M |
| Total Debt | $52.25B | $36.63B | $35.75B | $41.49B |
| Net Debt | $13.78B | $12.53B | $15.77B | $16.61B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan